Drugs Made In America Acquisition II Corp. (DMII)
Q2-CY2026Q1-CY2026Q4-CY2025Q3-CY2025Q2-CY2025Q1-CY2025Q4-CY2024Q3-CY2024Q2-CY2024Q1-CY2024Q4-CY2023Q3-CY2023Q2-CY2023Q1-CY2023Q4-CY2022Q3-CY2022Q2-CY2022Q1-CY2022Q4-CY2021Q3-CY2021Q2-CY2021Q1-CY2021Q4-CY2020Q3-CY2020Q2-CY2020Q1-CY2020Q4-CY2019Q3-CY2019Q2-CY2019Q1-CY2019Q4-CY2018Q3-CY2018Q2-CY2018Q1-CY2018Q4-CY2017Q3-CY2017Q2-CY2017Q1-CY2017Q4-CY2016Q3-CY2016Q2-CY2016Q1-CY2016Q4-CY2015Q3-CY2015Q2-CY2015Q1-CY2015Q4-CY2014Q3-CY2014Q2-CY2014
Balance Sheet Date2025-Dec-312025-Sep-30
Fiscal PeriodQ4-FY2025Q3-FY2025
Total Assets504,959,837$501,005,711$138,064$
Total Current Assets26,037$896,356$59,615$
Cash and Cash Equivalents223$
Receivables
Other Current Assets
Assets Held for Sale in Short Term
Total Noncurrent Assets504,933,800$500,109,355$78,449$
Goodwill
Other Intangible Assets
Physical Assets
Other Noncurrent Assets
Assets Held for Sale in Long Term
Total Liabilities17,800,864$18,177,345$254,783$
Total Current Liabilities300,864$677,345$254,783$
Accounts Payable99,359$4,592$
Short Term Debt
Short Term Capital Lease Obligations
Other Current Liabilities
Total Noncurrent Liabilities17,500,000$17,500,000$0$
Long Term Debt
Long Term Capital Lease Obligations
Other Noncurrent Liabilities
Total Equity(17,774,827$)(17,280,989$)(214,119$)(176,046$)(116,719$)(6,684$)
Equity to Minority
Equity to Common Shareholders(17,774,827$)(17,280,989$)(214,119$)(176,046$)(116,719$)(6,684$)
Additional Paid-In Capital33,563$
Retained Earnings(17,776,196$)(17,282,546$)(151,719$)
Treasury Stock
Capital Lease Obligations